ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) – Stock analysts at HC Wainwright raised their Q3 2026 EPS estimates for ACADIA Pharmaceuticals in a research report issued on Wednesday, August 5th. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q4 2026 earnings at $0.20 EPS and FY2027 earnings at $1.89 EPS. Get ACADIA Pharmaceuticals alerts:A number of other brokerages have also recently issued reports on ACAD. ACADIA Pharmaceuticals Price PerformanceShares of ACAD opened at $28.80 on Thursday. Key ACADIA Pharmaceuticals NewsHere are the key news stories impacting ACADIA Pharmaceuticals this week:Positive Sentiment: Second-quarter results exceeded expectations.